HGH Fragment 176-191
Metabolic · By Preptide Pro editorial team · Last updated
HGH Fragment 176-191 is a metabolic peptide, and it is not FDA-approved. A fragment from the C-terminal end of human growth hormone. It has been studied in animals and small human trials for fat metabolism.
Not FDA-approvedChemistry (PubChem)
No matching PubChem compound record was found under this name.
Is HGH Fragment 176-191 FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on HGH Fragment 176-191?
PubMed lists 3 records for “"hGH fragment" 176-191 OR "HGH 176-191"”, of which 0 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. | Analyst | 2026 Jul 27 |
| The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. | Front Endocrinol (Lausanne) | 2026 |
| Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. | Drug Des Devel Ther | 2022 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.